#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.

POST Online Media Lite Edition


Change in Alcon chairmanship

Staff writer |
Huenenberg, Switzerland - November 24, 2010, Huenenberg, Switzerland - Alcon, an eye care company, announced that Daniel Vasella, chairman of Novartis AG, has replaced Cary Rayment as chairman of the Alcon board of directors.

Dr. Vasella joined Alcon, Inc. board in July 2008 following the closing of the sale of the 24.85 percent minority interest of Alcon, Inc. by Nestlé S.A. to Novartis AG. Dr. Vasella was appointed chairman of the board on October 24, 2010.

Since 1996 Dr. Vasella has served as Chief Executive Officer of the Novartis Group and as executive member of the Board of Directors of Novartis AG. In 1999, he additionally was appointed Chairman of the Board of Directors of Novartis AG.

Dr. Vasella graduated with an M.D. from the University of Berne in 1979. After holding a number of medical positions in Switzerland, he joined Sandoz Pharmaceuticals Corporation in the U.S.A. in 1988. From 1993 to 1995, Dr. Vasella advanced from Head of Corporate Marketing to Senior Vice President and Head of Worldwide Development to Chief Operating Officer of Sandoz Pharma Ltd. In 1995 and 1996, he was a member of the Sandoz Group Executive Committee and Chief Executive Officer of Sandoz Pharma Ltd.

Dr. Vasella is a member of the Board of Directors of Pepsico, Inc., United States, a member of the Board of Dean’s Advisors at the Harvard Business School, and a member of the INSEAD Board of Directors.


Swiss Re appoints Hadi Riachi as India CEO
Credit Suisse appoints Thomas Gottstein as CEO
Primex Pharmaceuticals appoints Dan Spacie as global commercial head
SR Technics appoints Jean-Marc Lenz as CEO
Julius Baer appointed Philipp Rickenbacher as CEO

What to read next

Jacqualyn A. Fouse new CFO at The Perrigo Company
AZZ appoints Ed McGough to board of directors
Alcon: Robert Karsunky new chief financial officer